Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.
Aspergillus ustus is an uncommon clinical species which is poorly susceptible to antifungals. We report two cases of A. ustus infections that occurred in allogeneic stem cell transplant recipients while they were receiving either voriconazole or caspofungin. Prolonged use of these new antifungal agents may increase the risk of the emergence of resistant organisms.
Pavie
Juliette
J
Service d'Hématologie-Greffe de Moelle, Hôpital Saint-Louis, Paris, France.
Lacroix
Claire
C
Hermoso
Dea Garcia
DG
Robin
Marie
M
Ferry
Christèle
C
Bergeron
Anne
A
Feuilhade
Martine
M
Dromer
Françoise
F
Gluckman
Eliane
E
Molina
Jean-Michel
JM
Ribaud
Patricia
P
D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000382:microbiology / Q000517:prevention & control*; D001230:Aspergillus / Q000187:drug effects*; D000077336:Caspofungin; D018890:Chemoprevention; D025141:Drug Resistance, Fungal; D054714:Echinocandins; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D055666:Lipopeptides; D008297:Male; D010456:Peptides, Cyclic / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000009:adverse effects; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D000077336:Caspofungin; D065819:Voriconazole